RxSight, Inc. (RXST) SEC Filings & Earnings Calls

Dependence on Alcon collaboration

“We are dependent on our collaboration with Alcon for the development and commercialization of the Collaboration Products, and we have limited control over Alcon's performance under the collaboration.” · word for word

Contingent milestone payments

“A substantial portion of the payments contemplated by the RxSight-Alcon Collaboration Agreement is contingent, and the agreement may be terminated before we realize its anticipated benefits.” · word for word

Revenue decline and net losses

“While sales declined in 2025 and in the first half of 2026 following several years of rapid growth” · word for word

Supply chain and tariff risk

“We import from China certain materials and other components for use in our products, and such goods are subject to tariffs. Increases in tariffs could result in increased costs.” · word for word

Securities class action litigation

“Current and future litigation proceedings could adversely affect our business, including the putative securities class action complaint filed in July 2025 in the U.S. District Court for the Central District of California which is pending.” · word for word

Product sales decline and competitive pressure

“Product sales down 19% YoY due to heightened competitive trialing and consumer sentiment pressure.”

Guidance withdrawal creates uncertainty

“Withdrew 2026 guidance; new CEO conducting comprehensive business review.”

Gross margin pressure from inventory costs

“Gross margin excluding collaboration decreased from 74.9% to 71.2% due to inventory-related costs.”

Leadership transition risk; new CEO lacks ophthalmic device experience.

“CEO change from founder to commercial executive; no guidance update.”

Competitive trialing headwinds pressuring sales; guidance cut reflects demand uncertainty.

“While we faced meaningful commercial headwinds in Q2, including from more widespread competitive trialing” · word for word

Preliminary results subject to finalization and audit review.

“These preliminary estimates are based on information available to management as of the date of this press release and certain related assumptions, which could prove incorrect.” · word for word

Sales decline and growth uncertainty

“While sales declined in 2025 and in the first quarter of 2026 following several years of rapid growth, we have implemented changes in our sales organization in an effort to return to revenue growth in absolute dollars.” · word for word

History of net losses and expected continued losses

“We have incurred losses from operations since our inception and expect to continue to incur losses from operations in the future.” · word for word

Supply chain constraints and inflation

“The expansion of global lead times has resulted in the lack of availability of raw materials, including semiconductors, computers, monitors electronic parts, metals, packaging, adhesives, chemicals, resins and subcontract painted components.” · word for word

Tariff exposure on imports from China

“We import from China certain materials and other components for use in our products, and such goods are subject to tariffs. Increases in tariffs could result in increased costs.” · word for word

Revenue decline and widening losses; demand weakness in LDD sales and flat procedure growth.

“Q1 sales down 18.5% YoY; LAL procedures decreased 0.4% YoY; net loss nearly doubled.”

Revenue decline and increased operating losses

“Sales for 2025 were $134.5 million, a decrease of $5.4 million or 3.9%, compared to 2024. Loss from operations was $48.2 million for 2025, compared to $36.9 million in 2024.” · word for word

CFO transition

“Shelley Thunen resigned as our Chief Financial Officer effective January 11, 2026.” · word for word

Reimbursement and pricing pressure

“Any decline in the amount that payors reimburse doctors performing cataract procedures, or any reduction in the flexibility to charge patients for non-reimbursed procedures could make it difficult for us to convince our customers to make the up-front investment in our LDD.” · word for word

Malpractice insurance availability for customers

“Medical malpractice carriers are withdrawing coverage in certain states or substantially increasing premiums.” · word for word

International expansion regulatory risk

“We intend to expand sales of our products internationally in the future, but we may experience difficulties in obtaining regulatory clearance or approval or in successfully marketing our products internationally even if approved.” · word for word

Revenue decline and margin compression due to lower LDD capital equipment sales, indicating potential demand weakness for the system.

“FY2026 revenue guidance midpoint below FY2025 actual; gross margin guidance 70-72% vs 76.6% in FY2025.”

Preliminary results subject to audit completion; final numbers may differ.

“The company’s fourth quarter and full-year 2025 financial and operational results are preliminary and are subject to the completion of the company’s 2025 audit.” · word for word

CFO transition may cause temporary operational disruption, but company reaffirms FY2025 outlook.

“CFO transition with transition and consulting agreements; company reaffirms FY2025 outlook unchanged.”

Key executive departure could create temporary uncertainty, but transition plan mitigates risk.

“CFO transition with consulting agreement to ensure continuity”

Revenue concentration on LDD capital equipment

“LDD revenue declined 69% YoY, indicating lumpy capital equipment sales”

Continued operating losses

“The Company expects to continue to incur net operating losses into the foreseeable future” · word for word

Revenue decline driven by LDD sales drop; procedure volume growth may not sustain revenue recovery.

“LDD revenue decreased 69% compared to the third quarter of 2024” · word for word